A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy
Experimental Dermatology · 2023
DOI: 10.1111/exd.14829 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Nika Kianfar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Razi Dermatology Hospital, Autoimmune Bullous Diseases Research Center, School of Medicine, Tehran University of Medical S…. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Epidermolysis Bullosa Acquisita, Pemphigus, Autoimmune Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 97 Literaturangaben.
Abstract (Originalsprache)
Autoimmune bullous diseases (AIBDs) are a group of rare blistering dermatoses of the mucous membrane and/or skin. The efficacy, safety and treatment durability of intravenous immunoglobulin (IVIg) as an alternative treatment should be explored to systematically review the available literature regarding treatment outcomes with IVIg in AIBD patients. The predefined search strategy was incorporated into the following database, MEDLINE/PubMed, Embase, Scopus and Web of Science on 18 July 2022. Sixty studies were enrolled using Preferred Reporting Items for Systematic Reviews and Meta‐analyses guidelines. The use of IVIg alone or combined with rituximab was reported in 500 patients with pemphigus, 82 patients with bullous pemphigoid, 146 patients with mucous membranes pemphigoid and 19 patients with epidermolysis bullosa acquisita. Disease remission with IVIg therapy and RTX + IVIg combination therapy were recorded as 82.8% and 86.7% in pemphigus, 88.0% and 100% in bullous pemphigoid and 91.3% and 75.0% in mucous membrane pemphigoid, respectively. In epidermolysis bullosa acquisita, treatment with IVIg led to 78.6% disease remission; no data were available regarding the treatment with RTX + IVIg in this group of patients. Among all the included patients, 37.5% experienced at least one IVIg‐related side effect; the most common ones were headaches, fever/chills and nausea/vomiting. The use of IVIg with or without rituximab had a favourable clinical response in patients with AIBDs. IVIg has no major influence on the normal immune system, which makes its utilization for patients with AIBDs reasonable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Razi Dermatology Hospital, Autoimmune Bullous Diseases Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Nika Kianfar, Zeinab Aryanian, Azadeh Goodarzi
Zitieren
APA
Kianfar, N., Dasdar, S., Daneshpazhooh, M., Aryanian, Z., & Goodarzi, A. (2023). A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy. Experimental Dermatology. https://doi.org/10.1111/exd.14829
Vancouver
Kianfar N, Dasdar S, Daneshpazhooh M, Aryanian Z, Goodarzi A. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy. Experimental Dermatology. 2023. doi:10.1111/exd.14829
BibTeX
@article{Kianfar2023,
author = {Kianfar, Nika and Dasdar, Shayan and Daneshpazhooh, Maryam and Aryanian, Zeinab and Goodarzi, Azadeh},
title = {A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy},
journal = {Experimental Dermatology},
year = {2023},
doi = {10.1111/exd.14829}
}
EUVIMED